Pannex Therapeutics is a pre-clinical stage biotechnology company built around Pannexin 1 (Panx1), a novel and exciting target in pain and neurobiology.
We are building first-in-class Panx1 channel blockers designed to treat chronic neuropathic pain—an area of high unmet need with limited options for patients.
Beyond pain, Panx1 plays a fundamental role in cell signaling and disease biology, creating an exciting platform with broad therapeutic potential.
Panx1 channels are increasingly recognized as key drivers of chronic neuropathic pain and nervous system dysfunction.
Our focus on Panx1 reflects strong scientific validation and the opportunity to deliver meaningful benefit to patients.
We are developing potent and selective Panx1 channel blockers with the potential to set a new standard of care.
Our lead programs are optimized for efficacy, safety, and brain penetration to address peripheral and central pain mechanisms.
Deep understanding of Panx1 biology in pain and neuroinflammation enables precise target engagement and translational design.
Panx1 is implicated in multiple neurological and inflammatory conditions beyond pain, creating long-term platform value.
Panx1 research leader and life-sciences entrepreneur with extensive experience translating scientific research into drug-development programs.
30+ years across biopharma, commercialization, strategy and venture investing, including leadership roles in global pharmaceutical companies and emerging biotechnology.
Drug-discovery and translational-development veteran with more than 30 years in pharmaceutical R&D across CNS and oncology.